Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

Completed

Conditions studied: Skin Rash

In brief

The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).

Key facts

Study ID

NCT00709878

Run by

Northwestern University

People needed

32

Starts

2008-04-01

Expected to finish

2010-08-01

Last updated by the study team

2015-03-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients treated with lapatinib who developed skin toxicities and were biopsied.
• Patients treated with erlotinib, cetuximab, or panitumumab who have been biopsied for skin rash.

You may not qualify if…

• Patients who do not fit above criteria.

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.